ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tocilizumab

Also written as “Tocilizumab”, “tocilizumab [RoActemra/Actemra]” and “MRA(Tocilizumab)”.

Its studies are mostly in Arthritis, Rheumatoid · Arthritis, Juvenile · COVID-19 · Scleroderma, Systemic · Giant Cell Arteritis, led by 9 companies.

Drug pageTocilizumab: every studyMany companies study it; this page follows only the 129 they lead. All 336 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 9, 2009129 company-led studies, 4 open or runningNext primary completion: Jul 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only1162 open or runningphase 4since Nov 9, 2009Mar 25, 2005Jul 30, 2027phase 2 · NCT04524871
Bio-Thera Solutionsits history only30 open or runningphase 3since Jan 22, 2019Jul 12, 2018none ahead
Bristol-Myers Squibbits history only22 open or runningphase 3since Jan 9, 2026Feb 7, 2025Nov 14, 2028phase 3 · NCT07335562
Fresenius Kabiits history only20 open or runningphase 3since Aug 11, 2020Aug 30, 2017none ahead
JW Pharmaceuticalits history only20 open or runningphase 3since Sep 29, 2010Sep 29, 2010none ahead
Beijing VDJBioits history only10 open or runningphase 2since Jul 11, 2023Jul 11, 2023none ahead
Biogenits history only10 open or runningphase 1since Feb 8, 2024Feb 8, 2024none ahead
Celltrion10 open or runningphase 3since Feb 2, 2023Feb 2, 2023none ahead
Mycenax Biotechits history only10 open or runningphase 1since Apr 11, 2018Apr 11, 2018none ahead

Also a collaborator on its studies: Gilead Sciences, Pfizer, Adagene, Tempest Therapeutics, NiKang Therapeutics and Immune-Onc Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Celltrion only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 2, 2023First study: phase 3 study in Arthritis, RheumatoidFirst studyNCT05725434 · 30 enrolled

TargetBeta

IL6R →read by rule
“A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity”NCIt, by rule
“Interleukin-6 receptor alpha subunit inhibitor”ChEMBL 37, by rule

Other programs on IL6R

ProgramCompanyFurthest phaseStudies
sarilumabruleSanofiphase 427

Studies

The one study Celltrion leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05725434Arthritis, Rheumatoid3UNKNOWNApr 1, 202330

How it is read

Names in the registry

  • “Tocilizumab”, 54 entries
  • “tocilizumab [RoActemra/Actemra]”, 47 entries
  • “MRA(Tocilizumab)”, 11 entries
  • “tocilizumab”, 6 entries
  • “MSB11456”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.